INHIBIKASE THERAPEUTICS INC (IKT)
US45719W2052 - Common Stock
Taking everything into account, IKT scores 1 out of 10 in our fundamental rating. IKT was compared to 568 industry peers in the Biotechnology industry. IKT has a bad profitability rating. Also its financial health evaluation is rather negative. IKT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
IKT had negative earnings in the past year.
In the past year IKT has reported a negative cash flow from operations.
In the past 5 years IKT always reported negative net income.
IKT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -447.01%, IKT is doing worse than 97.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -447.01% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-79.46%
ROA(5y)-2911.53%
ROE(3y)-99.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IKT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IKT has more shares outstanding
The number of shares outstanding for IKT has been increased compared to 5 years ago.
IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
IKT has an Altman-Z score of -15.36. This is a bad value and indicates that IKT is not financially healthy and even has some risk of bankruptcy.
IKT has a worse Altman-Z score (-15.36) than 83.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.36 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
A Current Ratio of 0.85 indicates that IKT may have some problems paying its short term obligations.
IKT has a Current ratio of 0.85. This is amonst the worse of the industry: IKT underperforms 89.56% of its industry peers.
IKT has a Quick Ratio of 0.85. This is a bad value and indicates that IKT is not financially healthy enough and could expect problems in meeting its short term obligations.
IKT has a worse Quick ratio (0.85) than 88.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 |
3. Growth
3.1 Past
IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.17%, which is quite impressive.
IKT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
The Revenue for IKT have been decreasing by -42.21% on average. This is quite bad
EPS 1Y (TTM)33.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.42%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-28.07%
Revenue growth 5Y-42.21%
Sales Q2Q%-100%
3.2 Future
IKT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.59% yearly.
The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad
EPS Next Y74.44%
EPS Next 2Y36.81%
EPS Next 3Y22.59%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IKT's earnings are expected to grow with 22.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.81%
EPS Next 3Y22.59%
5. Dividend
5.1 Amount
IKT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INHIBIKASE THERAPEUTICS INC
NASDAQ:IKT (12/20/2024, 8:18:18 PM)
After market: 3.27 +0.07 (+2.19%)3.2
+0.04 (+1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners22.72%
Inst Owner Change2.84%
Ins Owners12.02%
Ins Owner Change0.88%
Market Cap215.01M
Analysts82.86
Price Target7.14 (123.12%)
Short Float %0.55%
Short Ratio0.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.73%
Min EPS beat(2)-73.94%
Max EPS beat(2)2.47%
EPS beat(4)3
Avg EPS beat(4)-9.38%
Min EPS beat(4)-73.94%
Max EPS beat(4)25.45%
EPS beat(8)5
Avg EPS beat(8)-4.51%
EPS beat(12)7
Avg EPS beat(12)-4.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-39.13%
EPS NQ rev (1m)-30%
EPS NQ rev (3m)75.93%
EPS NY rev (1m)-57.1%
EPS NY rev (3m)64.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.68
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -447.01% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-79.46%
ROA(5y)-2911.53%
ROE(3y)-99.21%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.64% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.85 | ||
| Quick Ratio | 0.85 | ||
| Altman-Z | -15.36 |
F-Score2
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.42%
EPS Next Y74.44%
EPS Next 2Y36.81%
EPS Next 3Y22.59%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y-28.07%
Revenue growth 5Y-42.21%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-0.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y3.59%
OCF growth 3YN/A
OCF growth 5YN/A